Though most women with endometrial cancer have a good prognosis, some with early-stage, low-grade endometrial cancer experience a recurrence. When the cancer recurs, it’s often resistant to chemotherapy and can be deadly.
New Masonic Cancer Center research suggests that a biomarker may indicate this recurrence risk.
Supported by the Minnesota Ovarian Cancer Alliance, Randy Shaver Cancer Research and Community Fund, and the U.S. Department of Defense Ovarian Cancer Research Program, the U’s Martina Bazzaro found that women with high levels of a specific enzyme are seven times more likely to experience a recurrence than women with low levels. She’s leading an international effort to validate the findings.